Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;20(1):81-87.
doi: 10.1111/ner.12534. Epub 2016 Oct 12.

Neurotransmitter Mechanisms Underlying Sacral Neuromodulation of Bladder Overactivity in Cats

Affiliations

Neurotransmitter Mechanisms Underlying Sacral Neuromodulation of Bladder Overactivity in Cats

Jathin Bandari et al. Neuromodulation. 2017 Jan.

Abstract

Objective: To determine the role of opioid, β-adrenergic, and metabotropic glutamate 5 receptors in sacral neuromodulation of bladder overactivity.

Material and methods: In α-chloralose anesthetized cats, intravesical infusion of 0.5% acetic acid (AA) irritated the bladder and induced bladder overactivity. Electric stimulation (5 Hz, 0.2 ms, 0.16-0.7V) of S1 or S2 sacral dorsal roots inhibited the bladder overactivity. Naloxone, propranolol, or MTEP were given intravenously (i.v.) to determine different neurotransmitter mechanisms.

Results: AA significantly (p < 0.05) reduced bladder capacity to 7.7 ± 3.3 mL from 12.0 ± 5.0 mL measured during saline infusion. S1 or S2 stimulation at motor threshold intensity significantly (p < 0.05) increased bladder capacity to 179.4 ± 20.0% or 219.1 ± 23.0% of AA control, respectively. Naloxone (1 mg/kg) significantly (p < 0.001) reduced the control capacity to 38.3 ± 7.3% and the bladder capacity measured during S1 stimulation to 106.2 ± 20.8% of AA control, but did not significantly change the bladder capacity measured during S2 stimulation. Propranolol (3 mg/kg) significantly (p < 0.01) reduced bladder capacity from 251.8 ± 32.2% to 210.9 ± 33.3% during S2 stimulation, but had no effect during S1 stimulation. A similar propranolol effect also was observed in naloxone-pretreated cats. In propranolol-pretreated cats during S1 or S2 stimulation, MTEP (3 mg/kg) significantly (p < 0.05) reduced bladder capacity and naloxone (1 mg/kg) following MTEP treatment further reduced bladder capacity. However, a significant inhibition could still be induced by S1 or S2 stimulation after all three drugs were administered.

Conclusions: Neurotransmitter mechanisms in addition to those activating opioid, β-adrenergic, and metabotropic glutamate 5 receptors also are involved in sacral neuromodulation.

Keywords: Bladder; cat; neuromodulation; neurotransmitter.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors reported no conflict of interest.

Figures

Figure 1
Figure 1
Effect of naloxone on inhibition of bladder overactivtiy induced by S1 or S2 dorsal root stimulation at motor threshold (T) intensity. a. Typical CMG traces from a cat. The black bar under the pressure trace indicates the stimulation duration. Stimulation: 5 Hz, 0.2 ms, T = 0.3V for S1, T = 0.16V for S2. Infusion rate = 2 mL/min. b. Normalized bladder capacity measured during repeated CMGs before and after naloxone treatment (N = 11 cats). * indicates a significant (p <0.001, two-way ANOVA) difference before and after naloxone treatment. # or $ indicates significantly (p <0.05, one-way ANOVA) different from control in the same treatment group.
Figure 2
Figure 2
Effect of propranolol on inhibition of bladder overactivity induced by S1 or S2 dorsal root stimulation at motor threshold (T) intensity. a. Typical CMG traces from a cat. The black bar under the pressure trace indicates stimulation duration. Stimulation: 5 Hz, 0.2 ms, T = 0.24V for S1, T = 0.2V for S2. Infusion rate = 2 mL/min. b. Normalized bladder capacity measured during repeated CMGs before and after propranolol treatment (N = 13 cats). * indicates a significant (p <0.01, two-way ANOVA) difference before and after propranolol treatment. # or $ indicates significantly (p <0.01, one-way ANOVA) different from control in the same treatment group.
Figure 3
Figure 3
Effect of propranolol on inhibition of bladder overactivity induced by S1 or S2 dorsal root stimulation at motor threshold (T) intensity in naloxone-pretreated cats. a. Typical CMG traces from a cat. The black bar under the pressure trace indicates stimulation duration. Stimulation: 5 Hz, 0.2 ms, T = 0.3V for S1, T = 0.26V for S2. Infusion rate = 3 mL/min. b. Normalized bladder capacity measured during repeated CMGs before and after propranolol treatment in naloxone-pretreated cats (N = 11). * indicates a significant (p <0.001, two-way ANOVA) difference before and after propranolol treatment. # or $ indicates significantly (p <0.05, one-way ANOVA) different from control in the same treatment group.
Figure 4
Figure 4
Effect of MTEP on inhibition of bladder overactivtiy induced by S1 or S2 dorsal root stimulation at motor threshold (T) intensity in propranolol-pretreated cats. a. Typical CMG traces from a cat. The black bar under the pressure trace indicates stimulation duration. Stimulation: 5 Hz, 0.2 ms, T = 0.7V for S1, T = 0.5V for S2. Infusion rate = 1 mL/min. b. Normalized bladder capacity measured during repeated CMGs before and after MTEP treatment in propranolol-pretreated cats (N = 13). * indicates a significant (p <0.05, two-way ANOVA) difference before and after MTEP treatment. # or $ indicates significantly (p <0.01, one-way ANOVA) different from control in the same treatment group.
Figure 5
Figure 5
Effect of naloxone on inhibition of bladder overactivity induced by S1 or S2 dorsal root stimulation at motor threshold (T) intensity in propranolol and MTEP-pretreated cats. a. Typical CMG traces from a cat. The black bar under the pressure trace indicates stimulation duration. Stimulation: 5 Hz, 0.2 ms, T = 0.4V for S1, T = 0.3V for S2. Infusion rate = 3 mL/min. b. Normalized bladder capacity measured during repeated CMGs before and after naloxone treatment in propranolol and MTEP-pretreated cats (N = 12). * indicates a significant (p <0.001, two-way ANOVA) difference before and after naloxone treatment. # or $ indicates significantly (p <0.05, one-way ANOVA) different from control in the same treatment group.

Similar articles

Cited by

References

    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37–49. - PubMed
    1. Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–1854. - PubMed
    1. Larson JA, Ogagan PD, Chen G, et al. Involvement of metabotropic glutamate receptor 5 in pudendal inhibition of nociceptive bladder activity in cats. J Physiol. 2011;589:5833–5843. - PMC - PubMed
    1. van Kerrebroeck PEV, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol. 2007;178:2029–2034. - PubMed
    1. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183:1438–1443. - PubMed

MeSH terms